Multisystem inflammatory syndrome in children and Kawasaki disease: a critical comparison

Chetan Sharma, Madhusudan Ganigara, Caroline Galeotti, Joseph Burns, Fernando M Berganza, Denise A Hayes, Davinder Singh-Grewal, Suman Bharath, Sujata Sajjan, Jagadeesh Bayry, Chetan Sharma, Madhusudan Ganigara, Caroline Galeotti, Joseph Burns, Fernando M Berganza, Denise A Hayes, Davinder Singh-Grewal, Suman Bharath, Sujata Sajjan, Jagadeesh Bayry

Abstract

Children and adolescents infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are predominantly asymptomatic or have mild symptoms compared with the more severe coronavirus disease 2019 (COVID-19) described in adults. However, SARS-CoV-2 is also associated with a widely reported but poorly understood paediatric systemic vasculitis. This multisystem inflammatory syndrome in children (MIS-C) has features that overlap with myocarditis, toxic-shock syndrome and Kawasaki disease. Current evidence indicates that MIS-C is the result of an exaggerated innate and adaptive immune response, characterized by a cytokine storm, and that it is triggered by prior SARS-CoV-2 exposure. Epidemiological, clinical and immunological differences classify MIS-C as being distinct from Kawasaki disease. Differences include the age range, and the geographical and ethnic distribution of patients. MIS-C is associated with prominent gastrointestinal and cardiovascular system involvement, admission to intensive care unit, neutrophilia, lymphopenia, high levels of IFNγ and low counts of naive CD4+ T cells, with a high proportion of activated memory T cells. Further investigation of MIS-C will continue to enhance our understanding of similar conditions associated with a cytokine storm.

Conflict of interest statement

The authors declare no competing interests.

© 2021. Springer Nature Limited.

Figures

Fig. 1. The temporal relationship between SARS-CoV-2…
Fig. 1. The temporal relationship between SARS-CoV-2 infection and development of MIS-C.
Evidence suggests that a relationship exists between the timing of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and development of multisystem inflammatory syndrome in children (MIS-C). Cases of MIS-C tend to be seen 3–6 weeks after the peak of SARS-CoV-2 transmission in a community. Because of this time lag, MIS-C is associated with a strong anti-spike protein IgG response, but a weak IgM response. It should be noted that implication of SARS-CoV-2 as a triggering factor for the development of MIS-C has yet to be firmly established.
Fig. 2. Possible mechanisms implicated in aberrant…
Fig. 2. Possible mechanisms implicated in aberrant activation of immune cells in MIS-C.
Clinical signs of multisystem inflammatory syndrome in children (MIS-C) mostly appear several weeks after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. MIS-C might be triggered by dysregulation of immune responses following viral infection. Aberrant activation of immune cells in patients with MIS-C could result from several factors. Infection with particular variants of SARS-CoV-2 might trigger hyperinflammatory responses. Genetic predisposition resulting from variants in the genes that encode pattern recognition receptors, Fcγ receptors and components of the signalling cascades of immune response, as well as mutations in genes such as SOCS1, which regulate inflammatory responses, could all contribute to enhancement of inflammatory responses to infection. Dysregulated activation of lymphocytes, with production of IgG corresponding to microbial pathogens or autoantigens, could cause immune-complex-mediated innate-cell activation by signalling via Fcγ receptors. Production of autoantibodies could also lead to complement activation and autoantibody-mediated endothelial damage. SARS-CoV-2 spike (S) protein might function as a superantigen, contributing to activation of T cells. SOCS1, suppressor of cytokine signalling 1; TLR, Toll-like receptor.
Fig. 3. Comparative incidence of clinical signs…
Fig. 3. Comparative incidence of clinical signs in MIS-C and Kawasaki disease.
Percentage incidence of particular symptoms in patients with multisystem inflammatory syndrome in children (MIS-C) or Kawasaki disease is shown, with the values derived from published reports,,,–,,,,–. Although some clinical signs, such as fever and cervical lymphadenopathy are equally prevalent in both MIS-C and Kawasaki disease, the incidence of other symptoms, including shock, coronary artery involvement and gastrointestinal symptoms (vomiting, diarrhoea or abdominal pain), are characteristic of MIS-C. a‘Conjunctival injection’ refers to bilateral non-exudative conjunctivitis in Kawasaki disease. b‘Rash’ refers to polymorphous rash in Kawasaki disease. c‘Coronary artery dilation of aneurysm’ refers to incidence in untreated cases of Kawasaki disease.

References

    1. Lai C-C, et al. Global epidemiology of coronavirus disease 2019 (COVID-19): disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status. Int. J. Antimicrob. Agents. 2020;55:105946.
    1. Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Bio Med. Atenei Parm. 2020;91:157–160.
    1. Bikdeli B, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J. Am. Coll. Cardiol. 2020;75:2950–2973.
    1. Montalvan V, Lee J, Bueso T, De Toledo J, Rivas K. Neurological manifestations of COVID-19 and other coronavirus infections: a systematic review. Clin. Neurol. Neurosurg. 2020;194:105921.
    1. Clerkin KJ, et al. COVID-19 and cardiovascular disease. Circulation. 2020;141:1648–1655.
    1. Hoffman JIE, Kaplan S. The incidence of congenital heart disease. J. Am. Coll. Cardiol. 2002;39:1890–1900.
    1. Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M. The cytokine storm in COVID-19: an overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor. Rev. 2020;53:25–32.
    1. Ou X, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. Commun. 2020;11:1620.
    1. Hoffmann M, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and Is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–280.e8.
    1. Liu J, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020;55:102763.
    1. Verdoni L, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020;395:1771–1778.
    1. Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020;395:1607–1608.
    1. Feldstein LR, et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N. Engl. J. Med. 2020;383:334–346.
    1. Dufort EM, et al. Multisystem inflammatory syndrome in children in New York State. N. Engl. J. Med. 2020;383:347–358.
    1. Cheung EW, et al. Multisystem inflammatory syndrome related to COVID-19 in previously healthy children and adolescents in New York City. JAMA. 2020;324:294–296.
    1. Galeotti C, Bayry J. Autoimmune and inflammatory diseases following COVID-19. Nat. Rev. Rheumatol. 2020;16:413–414.
    1. Simpson JM, Newburger JW. Multi-system inflammatory syndrome in children in association with COVID-19. Circulation. 2020;142:437–440.
    1. Levin M. Childhood multisystem inflammatory syndrome — a new challenge in the pandemic. N. Engl. J. Med. 2020;383:393–395.
    1. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Arerugi. 1967;16:178–222.
    1. McCrindle Brian W, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017;135:e927–e999.
    1. Burns JC, et al. Genetic variations in the receptor-ligand pair CCR5 and CCL3L1 are important determinants of susceptibility to Kawasaki disease. J. Infect. Dis. 2005;192:344–349.
    1. Burgner D, et al. A genome-wide association study identifies novel and functionally related susceptibility loci for Kawasaki disease. PLoS Genet. 2009;5:e1000319.
    1. Burgner D, Harnden A. Kawasaki disease: what is the epidemiology telling us about the etiology? Int. J. Infect. Dis. 2005;9:185–194.
    1. Son MBF, Newburger JW. Kawasaki disease. Pediatr. Rev. 2018;39:78–90.
    1. Burns JC. The riddle of Kawasaki disease. N. Engl. J. Med. 2007;356:659–661.
    1. Holman RC, Curns AT, Belay ED, Steiner CA, Schonberger LB. Kawasaki syndrome hospitalizations in the United States, 1997 and 2000. Pediatrics. 2003;112:495–501.
    1. Kuijpers TW, et al. Kawasaki disease: a maturational defect in immune responsiveness. J. Infect. Dis. 1999;180:1869–1877.
    1. Green MS. The male predominance in the incidence of infectious diseases in children: a postulated explanation for disparities in the literature. Int. J. Epidemiol. 1992;21:381–386.
    1. Burgner D, Levin M. Genetic susceptibility to infectious diseases. Pediatr. Infect. Dis. J. 2003;22:1–6.
    1. Harnden A, Alves B, Sheikh A. Rising incidence of Kawasaki disease in England: analysis of hospital admission data. BMJ. 2002;324:1424–1425.
    1. Bell DM, Morens DM, Holman RC, Hurwitz ES, Hunter MK. Kawasaki syndrome in the United States 1976 to 1980. Am. J. Dis. Child. 1983;137:211–214.
    1. Chang R-KR. Hospitalizations for Kawasaki disease among children in the United States, 1988–1997. Pediatrics. 2002;109:e87.
    1. Du Z-D, et al. Epidemiologic picture of Kawasaki disease in Beijing from 1995 through 1999. Pediatr. Infect. Dis. J. 2002;21:103–107.
    1. Park Y-W, et al. Epidemiologic study of Kawasaki disease in Korea, 1997-1999: comparison with previous studies during 1991-1996. J. Korean Med. Sci. 2002;17:453–456.
    1. Uehara R, Belay ED. Epidemiology of Kawasaki disease in Asia, Europe, and the United States. J. Epidemiol. 2012;22:79–85.
    1. Yanagawa H, Yashiro M, Nakamura Y, Kawasaki T, Kato H. Results of 12 nationwide epidemiological incidence surveys of Kawasaki disease in Japan. Arch. Pediatr. Adolesc. Med. 1995;149:779–783.
    1. Burns JC, et al. Seasonality and temporal clustering of Kawasaki syndrome. Epidemiology. 2005;16:220–225.
    1. Nakamura Y, Yanagawa I, Kawasaki T. Temporal and geographical clustering of Kawasaki disease in Japan. Prog. Clin. Biol. Res. 1987;250:19–32.
    1. Yanagawa H, Nakamura Y, Kawasaki T, Shigematsu I. Nationwide epidemic of Kawasaki disease in Japan during winter of 1985-86. Lancet. 1986;2:1138–1139.
    1. Chang L-Y, et al. Viral infections associated with Kawasaki disease. J. Formos. Med. Assoc. 2014;113:148–154.
    1. Benseler SM, et al. Infections and Kawasaki disease: implications for coronary artery outcome. Pediatrics. 2005;116:e760–e766.
    1. Esper F, et al. Association between a novel human coronavirus and Kawasaki disease. J. Infect. Dis. 2005;191:499–502.
    1. Rowley AH, et al. Detection of antigen in bronchial epithelium and macrophages in acute Kawasaki disease by use of synthetic antibody. J. Infect. Dis. 2004;190:856–865.
    1. Cohen E, Sundel R. Kawasaki disease at 50 years. JAMA Pediatr. 2016;170:1093–1099.
    1. Rowley AH. Is Kawasaki disease an infectious disorder? Int. J. Rheum. Dis. 2018;21:20–25.
    1. Abe J, et al. Selective expansion of T cells expressing T-cell receptor variable regions Vβ2 and Vβ 8 in Kawasaki disease. Proc. Natl Acad. Sci. USA. 1992;89:4066–4070.
    1. Abe J, et al. Characterization of T cell repertoire changes in acute Kawasaki disease. J. Exp. Med. 1993;177:791–796.
    1. Curtis N, Zheng R, Lamb JR, Levin M. Evidence for a superantigen mediated process in Kawasaki disease. Arch. Dis. Child. 1995;72:308–311.
    1. Nagata S, et al. Heat shock proteins and superantigenic properties of bacteria from the gastrointestinal tract of patients with Kawasaki disease. Immunology. 2009;128:511–520.
    1. Pietra BA, Inocencio JD, Giannini EH, Hirsch R. TCR Vβ family repertoire and T cell activation markers in Kawasaki disease. J. Immunol. 1994;153:1881–1888.
    1. Mancia L, et al. Characterization of the T-cell receptor V-β repertoire in Kawasaki disease. Scand. J. Immunol. 1998;48:443–449.
    1. Jun JS, Jung YK, Lee DW. Relationship between vitamin D levels and intravenous immunoglobulin resistance in Kawasaki disease. Korean J. Pediatr. 2017;60:216–220.
    1. Canning MO, Grotenhuis K, de Wit H, Ruwhof C, Drexhage HA. 1-α,25-Dihydroxyvitamin D3 (1,25(OH)(2)D(3)) hampers the maturation of fully active immature dendritic cells from monocytes. Eur. J. Endocrinol. 2001;145:351–357.
    1. Ben-Shoshan M, et al. 1α,25-dihydroxyvitamin D3 (Calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells. Mol. Cancer Ther. 2007;6:1433–1439.
    1. Meyer K, et al. Breastfeeding and vitamin D supplementation reduce the risk of Kawasaki disease in a German population-based case-control study. BMC Pediatr. 2019;19:66.
    1. Stagi S, Rigante D, Lepri G, Matucci Cerinic M, Falcini F. Severe vitamin D deficiency in patients with Kawasaki disease: a potential role in the risk to develop heart vascular abnormalities? Clin. Rheumatol. 2016;35:1865–1872.
    1. Chen Y-L, Wang J-L, Li W-Q. Prediction of the risk of coronary arterial lesions in Kawasaki disease by serum 25-hydroxyvitamin D3. Eur. J. Pediatr. 2014;173:1467–1471.
    1. Kim S, Eun LY. Iron deficiency anemia as a predictor of coronary artery abnormalities in Kawasaki disease. Korean J. Pediatr. 2019;62:301–306.
    1. Belkaid Y, Hand T. Role of the microbiota in immunity and inflammation. Cell. 2014;157:121–141.
    1. Kaneko K, Akagawa S, Akagawa Y, Kimata T, Tsuji S. Our evolving understanding of Kawasaki disease pathogenesis: role of the gut microbiota. Front. Immunol. 2020;11:1616.
    1. Yamashiro Y, Nagata S, Ohtsuka Y, Oguchi S, Shimizu T. Microbiologic studies on the small intestine in Kawasaki disease. Pediatr. Res. 1996;39:622–624.
    1. Takeshita S, Kobayashi I, Kawamura Y, Tokutomi T, Sekine I. Characteristic profile of intestinal microflora in Kawasaki disease. Acta Paediatr. 2002;91:783–788.
    1. Chen J, et al. Altered gut microbiota correlated with systemic inflammation in children with Kawasaki disease. Sci. Rep. 2020;10:14525.
    1. Kumrah R, Vignesh P, Rawat A, Singh S. Immunogenetics of Kawasaki disease. Clin. Rev. Allergy Immunol. 2020;59:122–139.
    1. Holman RC, et al. Kawasaki syndrome in Hawaii. Pediatr. Infect. Dis. J. 2005;24:429–433.
    1. Fujita Y, et al. Kawasaki disease in families. Pediatrics. 1989;84:666–669.
    1. Onouchi Y, et al. Common variants in CASP3 confer susceptibility to Kawasaki disease. Hum. Mol. Genet. 2010;19:2898–2906.
    1. Shimizu C, et al. Transforming growth factor-beta signaling pathway in patients with Kawasaki disease. Circ. Cardiovasc. Genet. 2011;4:16–25.
    1. Chang L, Yang H-W, Lin T-Y, Yang KD. Perspective of immunopathogenesis and immunotherapies for Kawasaki disease. Front. Pediatr. 2021;9:697632.
    1. Alphonse MP, et al. Inositol-triphosphate 3-kinase c mediates inflammasome activation and treatment response in Kawasaki disease. J. Immunol. 2016;197:3481–3489.
    1. Onouchi Y. Molecular genetics of Kawasaki disease. Pediatr. Res. 2009;65:46R–54R.
    1. Burns JC. Cyclosporine and coronary outcomes in Kawasaki disease. J. Pediatr. 2019;210:239–242.
    1. Matsuda I, Hattori S, Nagata N, Fruse A, Nambu H. HLA antigens in mucocutaneous lymph node syndrome. Am. J. Dis. Child. 1977;131:1417–1418.
    1. Kato S, et al. HLA antigens in Kawasaki disease. Pediatrics. 1978;61:252–255.
    1. Krensky AM, Berenberg W, Shanley K, Yunis EJ. HLA antigens in mucocutaneous lymph node syndrome in New England. Pediatrics. 1981;67:741–743.
    1. Sharma K, et al. Epigenetics in Kawasaki disease. Front. Pediatr. 2021;9:626.
    1. Assari R, et al. Pro-inflammatory cytokine single nucleotide polymorphisms in Kawasaki disease. Int. J. Rheum. Dis. 2018;21:1120–1126.
    1. Weng K-P, et al. IL-1B polymorphism in association with initial intravenous immunoglobulin treatment failure in Taiwanese children with Kawasaki disease. Circ. J. 2010;74:544–551.
    1. Kim J-J, et al. Identification of KCNN2 as a susceptibility locus for coronary artery aneurysms in Kawasaki disease using genome-wide association analysis. J. Hum. Genet. 2013;58:521–525.
    1. Kwon Y-C, et al. Identification of the TIFAB gene as a susceptibility locus for coronary artery aneurysm in patients with Kawasaki disease. Pediatr. Cardiol. 2019;40:483–488.
    1. Lu Z, et al. P2RY12:rs7637803 TT variant genotype increases coronary artery aneurysm risk in Kawasaki disease in a southern Chinese population. J. Gene Med. 2019;21:e3066.
    1. Fu LY, et al. The IL-1B gene polymorphisms rs16944 and rs1143627 contribute to an increased risk of coronary artery lesions in southern Chinese children with Kawasaki disease. J. Immunol. Res. 2019;2019:4730507.
    1. Hara T, et al. Kawasaki disease: a matter of innate immunity. Clin. Exp. Immunol. 2016;186:134–143.
    1. Lee NH, Choi HJ, Kim YH. Clinical usefulness of serum procalcitonin level in distinguishing between Kawasaki disease and other infections in febrile children. Korean J. Pediatr. 2017;60:112–117.
    1. Tremoulet AH, et al. Increased incidence and severity of Kawasaki disease among Filipino-Americans in San Diego county. Pediatr. Infect. Dis. J. 2011;30:909–911.
    1. Burns JC, Glodé MP. Kawasaki syndrome. Lancet. 2004;364:533–544.
    1. Ikeda K, et al. Unique activation status of peripheral blood mononuclear cells at acute phase of Kawasaki disease. Clin. Exp. Immunol. 2010;160:246–255.
    1. Armaroli G, et al. Monocyte-derived interleukin-1β as the driver of S100A12-induced sterile inflammatory activation of human coronary artery endothelial cells: implications for the pathogenesis of Kawasaki disease. Arthritis Rheumatol. 2019;71:792–804.
    1. Zhang K, et al. Increase in T helper type 17 cells in children with Kawasaki disease is NR4A2 dependent. Eur. J. Inflamm. 2018;16:2058739218760945.
    1. Wu Y, et al. Interleukin-6 is prone to be a candidate biomarker for predicting incomplete and IVIG nonresponsive Kawasaki disease rather than coronary artery aneurysm. Clin. Exp. Med. 2019;19:173–181.
    1. Oharaseki T, et al. The role of TNF-α in a murine model of Kawasaki disease arteritis induced with a Candida albicans cell wall polysaccharide. Mod. Rheumatol. 2014;24:120–128.
    1. Lin CY, Lin CC, Hwang B, Chiang B. Serial changes of serum interleukin-6, interleukin-8, and tumor necrosis factor alpha among patients with Kawasaki disease. J. Pediatr. 1992;121:924–926.
    1. Guo MM-H, et al. Th17- and Treg-related cytokine and mRNA expression are associated with acute and resolving Kawasaki disease. Allergy. 2015;70:310–318.
    1. Lin C-Y, Lin C-C, Hwang B, Chiang BN. Cytokines predict coronary aneurysm formation in Kawasaki disease patients. Eur. J. Pediatr. 1993;152:309–312.
    1. Rahmani F, et al. Interleukin 10 and and transforming growth factor β polymorphisms as risk factors for Kawasaki disease: a case-control study and meta-analysis. Avicenna J. Med. Biotechnol. 2019;11:325–333.
    1. Jia S, Li C, Wang G, Yang J, Zu Y. The T helper type 17/regulatory T cell imbalance in patients with acute Kawasaki disease. Clin. Exp. Immunol. 2010;162:131–137.
    1. Yoshida Y, et al. Enhanced formation of neutrophil extracellular traps in Kawasaki disease. Pediatr. Res. 2020;87:998–1004.
    1. Papayannopoulos V. Neutrophil extracellular traps in immunity and disease. Nat. Rev. Immunol. 2018;18:134–147.
    1. Garcia-Romo GS, et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci. Transl. Med. 2011;3:73ra20.
    1. Kessenbrock K, et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat. Med. 2009;15:623–625.
    1. Corsiero E, Pratesi F, Prediletto E, Bombardieri M, Migliorini P. NETosis as source of autoantigens in rheumatoid arthritis. Front. Immunol. 2016;7:485.
    1. Grunebaum E, et al. The role of anti-endothelial cell antibodies in Kawasaki disease – in vitro and in vivo studies. Clin. Exp. Immunol. 2002;130:233–240.
    1. Consiglio CR, et al. The immunology of multisystem inflammatory syndrome in children with COVID-19. Cell. 2020;183:968–981.e7.
    1. Sakurai Y. Autoimmune aspects of Kawasaki disease. J. Investig. Allergol. Clin. Immunol. 2019;29:251–261.
    1. Nash MC, Shah V, Reader JA, Dillon MJ. Anti-neutrophil cytoplasmic antibodies and anti-endothelial cell antibodies are not increased in Kawasaki disease. Rheumatology. 1995;34:882–887.
    1. Li CR, Yang XQ, Shen J, Li YB, Jiang LP. Immunoglobulin G subclasses in serum and circulating immune complexes in patients with Kawasaki syndrome. Pediatr. Infect. Dis. J. 1990;9:544–547.
    1. Levin M, et al. Platelet immune complex interaction in pathogenesis of Kawasaki disease and childhood polyarteritis. Br. Med. J. Clin. Res. Ed. 1985;290:1456–1460.
    1. Miyata K, et al. Circulation immune complexes and granulocytes chemotaxis in Kawasaki disease: the 8th conference on prevention for rheumatic fever and rheumatic heart disease. Jpn. Circ. J. 1984;48:1350–1353.
    1. Ono S, Onimaru T, Kawakami K, Hokonohara M, Miyata K. Impaired granulocyte chemotaxis and increased circulating immune complexes in Kawasaki disease. J. Pediatr. 1985;106:567–570.
    1. Kohsaka T, Abe J, Asahina T, Kobayashi N. Classical pathway complement activation in Kawasaki syndrome. J. Allergy Clin. Immunol. 1994;93:520–525.
    1. Biezeveld MH, et al. Polymorphisms in the mannose-binding lectin gene as determinants of age-defined risk of coronary artery lesions in Kawasaki disease. Arthritis Rheum. 2006;54:369–376.
    1. Ohshio G, et al. High levels of IgA-containing circulating immune complex and secretory IgA in Kawasaki disease. Microbiol. Immunol. 1987;31:891–898.
    1. Noval Rivas M, Arditi M. Kawasaki disease: pathophysiology and insights from mouse models. Nat. Rev. Rheumatol. 2020;16:391–405.
    1. Noval Rivas M, et al. Intestinal permeability and IgA provoke immune vasculitis linked to cardiovascular inflammation. Immunity. 2019;51:508–521.e6.
    1. Olivito B, et al. Defective FOXP3 expression in patients with acute Kawasaki disease and restoration by intravenous immunoglobulin therapy. Clin. Exp. Rheumatol. 2010;28:93–97.
    1. Abe J, et al. Gene expression profiling of the effect of high-dose intravenous Ig in patients with Kawasaki disease. J. Immunol. 2005;174:5837–5845.
    1. Yoshimura K, et al. Increased nitric oxide production by neutrophils in early stage of Kawasaki disease. Eur. J. Pediatr. 2009;168:1037–1041.
    1. Wang Y, et al. Evaluation of intravenous immunoglobulin resistance and coronary artery lesions in relation to Th1/Th2 cytokine profiles in patients with Kawasaki disease. Arthritis Rheum. 2013;65:805–814.
    1. Zhu YP, et al. Immune response to intravenous immunoglobulin in patients with Kawasaki disease and MIS-C. J. Clin. Invest. 2021 doi: 10.1172/JCI147076.
    1. Wang Z, et al. Single-cell RNA sequencing of peripheral blood mononuclear cells from acute Kawasaki disease patients. Nat. Commun. 2021;12:5444.
    1. Rambabu N, Mathew MJ, Kaveri SV, Bayry J. Boolean analysis of the transcriptomic data to identify novel biomarkers of IVIG response. Autoimmun. Rev. 2021;20:102850.
    1. Belhadjer Z, et al. Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic. Circulation. 2020;142:429–436.
    1. CDC. Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with Coronavirus Disease 2019 (COVID-19). Health Alert Network (2020).
    1. CDC. COVID Data Tracker. (2020).
    1. Kaushik S, et al. Multisystem inflammatory syndrome in children associated with severe acute respiratory syndrome coronavirus 2 infection (MIS-C): a multi-institutional study from New York City. J. Pediatr. 2020;224:24–29.
    1. Davies P, et al. Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study. Lancet Child Adolesc. Health. 2020;4:669–677.
    1. Pouletty M, et al. Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort. Ann. Rheum. Dis. 2020;79:999–1006.
    1. Toubiana J, et al. Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study. BMJ. 2020;369:m2094.
    1. Capone CA, et al. Characteristics, cardiac involvement, and outcomes of multisystem inflammatory syndrome of childhood associated with severe acute respiratory syndrome coronavirus 2 Infection. J. Pediatr. 2020;224:141–145.
    1. Hameed S, et al. Spectrum of imaging findings on chest radiographs, US, CT, and MRI images in multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19. Radiology. 2020;298:E1–E10.
    1. Whittaker E, et al. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA. 2020;324:259–269.
    1. Moraleda C, et al. Multi-inflammatory syndrome in children related to SARS-CoV-2 in Spain. Clin. Infect. Dis. 2020;72:e397–e401.
    1. Dhanalakshmi K, et al. Epidemiological and clinical profile of pediatric inflammatory multisystem syndrome — temporally associated with SARS-CoV-2 (PIMS-TS) in Indian children. Indian. Pediatr. 2020;57:1010–1014.
    1. Miller J, et al. Gastrointestinal symptoms as a major presentation component of a novel multisystem inflammatory syndrome in children that is related to coronavirus disease 2019: a single center experience of 44 cases. Gastroenterology. 2020;159:1571–1574.e2.
    1. Belot A, et al. SARS-CoV-2-related paediatric inflammatory multisystem syndrome, an epidemiological study, France, 1 March to 17 May 2020. Eurosurveillance. 2020;25:2001010.
    1. Lee PY, et al. Distinct clinical and immunological features of SARS–CoV-2–induced multisystem inflammatory syndrome in children. J. Clin. Invest. 2020;130:5942–5950.
    1. Riollano-Cruz M, et al. Multisystem inflammatory syndrome in children related to COVID-19: a New York City experience. J. Med. Virol. 2021;93:424–433.
    1. Ramcharan T, et al. Paediatric inflammatory multisystem syndrome: temporally associated with SARS-CoV-2 (PIMS-TS): cardiac features, management and short-term outcomes at a UK tertiary paediatric hospital. Pediatr. Cardiol. 2020;41:1391–1401.
    1. Grimaud M, et al. Acute myocarditis and multisystem inflammatory emerging disease following SARS-CoV-2 infection in critically ill children. Ann. Intensive Care. 2020;10:69.
    1. Perez-Toledo M, et al. SARS-CoV-2-specific IgG1/IgG3 but not IgM in children with pediatric inflammatory multi-system syndrome. Pediatr. Allergy Immunol. 2021;32:1125–1129.
    1. RCPCH. Paediatric multisystem inflammatory syndrome temporally associated with COVID-19. (2020).
    1. WHO. Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19. (2020).
    1. Carlin RF, et al. Discriminating multisystem inflammatory syndrome in children requiring treatment from common febrile conditions in outpatient settings. J. Pediatr. 2021;229:26–32.e2.
    1. Roberts JE, et al. Differentiating multisystem inflammatory syndrome in children: a single-centre retrospective cohort study. Arch. Dis. Child. 2021 doi: 10.1136/archdischild-2021-322290.
    1. García-Salido A, et al. Severe manifestations of SARS-CoV-2 in children and adolescents: from COVID-19 pneumonia to multisystem inflammatory syndrome: a multicentre study in pediatric intensive care units in Spain. Crit. Care. 2020;24:666.
    1. Hoang A, et al. COVID-19 in 7780 pediatric patients: a systematic review. EClinicalMedicine. 2020;24:100433.
    1. Mahase E. Covid-19: cases of inflammatory syndrome in children surge after urgent alert. BMJ. 2020;369:m1990.
    1. Henderson LA, et al. American College of Rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS–CoV-2 and Hyperinflammation in pediatric COVID-19: Version 1. Arthritis Rheumatol. 2020;72:1791–1805.
    1. Henderson LA, et al. American College of Rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: Version 2. Arthritis Rheumatol. 2021;73:e13–e29.
    1. Diorio C, et al. Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS–CoV-2. J. Clin. Invest. 2020;130:5967–5975.
    1. Duarte-Neto AN, et al. An autopsy study of the spectrum of severe COVID-19 in children: from SARS to different phenotypes of MIS-C. EclinicalMed. 2021;35:100850.
    1. Yonker LM, et al. Multisystem inflammatory syndrome in children is driven by zonulin-dependent loss of gut mucosal barrier. J. Clin. Invest. 2021;131:149633.
    1. Ramaswamy A, et al. Immune dysregulation and autoreactivity correlate with disease severity in SARS-CoV-2-associated multisystem inflammatory syndrome in children. Immunity. 2021;54:1083–1095.e7.
    1. Gruber CN, et al. Mapping systemic inflammation and antibody responses in multisystem inflammatory syndrome in children (MIS-C) Cell. 2020;183:982–995.e14.
    1. Rostad CA, et al. Quantitative SARS-CoV-2 serology in children with multisystem inflammatory syndrome (MIS-C) Pediatrics. 2020;146:e2020018242.
    1. Weisberg SP, et al. Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum. Nat. Immunol. 2021;22:25–31.
    1. Anderson EM, et al. SARS-CoV-2 antibody responses in children with MIS-C and mild and severe COVID-19. J. Pediatr. Infect. Dis. Soc. 2020;10:669–673.
    1. Bartsch YC, et al. Humoral signatures of protective and pathological SARS-CoV-2 infection in children. Nat. Med. 2021;27:454–462.
    1. Mateus J, et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science. 2020;370:89–94.
    1. Grifoni A, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181:1489–1501.e15.
    1. Sermet-Gaudelus I, et al. Prior infection by seasonal coronaviruses, as assessed by serology, does not prevent SARS-CoV-2 infection and disease in children, France, April to June 2020. Eur. Surveill. 2021;26:2001782.
    1. Rivas MN, Porritt RA, Cheng MH, Bahar I, Arditi M. COVID-19–associated multisystem inflammatory syndrome in children (MIS-C): a novel disease that mimics toxic shock syndrome — the superantigen hypothesis. J. Allergy Clin. Immunol. 2021;147:57–59.
    1. Cheng MH, et al. Superantigenic character of an insert unique to SARS-CoV-2 spike supported by skewed TCR repertoire in patients with hyperinflammation. Proc. Natl Acad. Sci. USA. 2020;117:25254–25262.
    1. Porritt RA, et al. HLA class I-associated expansion of TRBV11-2 T cells in multisystem inflammatory syndrome in children. J. Clin. Invest. 2021;131:e146614.
    1. Moreews M, et al. Polyclonal expansion of TCR Vβ 21.3+ CD4+ and CD8+ T cells is a hallmark of multisystem inflammatory syndrome in children. Sci. Immunol. 2021;6:eabh1516.
    1. McCormick JK, Yarwood JM, Schlievert PM. Toxic shock syndrome and bacterial superantigens: an update. Annu. Rev. Microbiol. 2001;55:77–104.
    1. Radujkovic A, et al. Vitamin D deficiency and outcome of COVID-19 patients. Nutrients. 2020;12:2757.
    1. Urashima M, et al. Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren. Am. J. Clin. Nutr. 2010;91:1255–1260.
    1. Omenetti S, Pizarro TT. The Treg/TH17 axis: a dynamic balance regulated by the gut microbiome. Front. Immunol. 2015;6:639.
    1. Yeoh YK, et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut. 2021;70:698–706.
    1. Zuo T, et al. Alterations in fecal fungal microbiome of patients with COVID-19 during time of hospitalization until discharge. Gastroenterology. 2020;159:1302–1310.e5.
    1. Merenstein C, et al. Signatures of COVID-19 severity and immune response in the respiratory tract microbiome. mBio. 2021;12:e0177721.
    1. Zuo T, et al. Alterations in gut microbiota of patients with COVID-19 during time of hospitalization. Gastroenterology. 2020;159:944–955.e8.
    1. Xu R, et al. Progressive deterioration of the upper respiratory tract and the gut microbiomes in children during the early infection stages of COVID-19. J. Genet. Genomics. 2021 doi: 10.1016/j.jgg.2021.05.004.
    1. Hurst, J. H. et al. Age-related changes in the upper respiratory microbiome are associated with SARS-CoV-2 susceptibility and illness severity. Preprint at medRxiv (2021).
    1. Chou J, et al. Mechanisms underlying genetic susceptibility to multisystem inflammatory syndrome in children (MIS-C) J. Allergy Clin. Immunol. 2021;148:732–738.e1.
    1. Belay ED, et al. Trends in geographic and temporal distribution of US children with multisystem inflammatory syndrome during the COVID-19 pandemic. JAMA Pediatr. 2021;175:837–845.
    1. Krishnan L, Ogunwole SM, Cooper LA. Historical insights on coronavirus disease 2019 (COVID-19), the 1918 influenza pandemic, and racial disparities: illuminating a path forward. Ann. Intern. Med. 2020;173:474–481.
    1. Alcendor DJ. Racial disparities-associated COVID-19 mortality among minority populations in the US. J. Clin. Med. 2020;9:2442.
    1. Rafferty MS, et al. Multisystem inflammatory syndrome in children (MIS-C) and the coronavirus pandemic: current knowledge and implications for public health. J. Infect. Public Health. 2021;14:484–494.
    1. Nguyen A, et al. Human leukocyte antigen susceptibility map for severe acute respiratory syndrome coronavirus 2. J. Virol. 2020;94:e00510–e00520.
    1. Zhang Q, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370:eabd4570v.
    1. Bastard P, et al. Insufficient type I IFN immunity underlies life-threatening COVID-19 pneumonia. C. R. Biol. 2021;344:19–25.
    1. Lee PY, et al. Immune dysregulation and multisystem inflammatory syndrome in children (MIS-C) in individuals with haploinsufficiency of SOCS1. J. Allergy Clin. Immunol. 2020;146:1194–1200.e1.
    1. Vella LA, et al. Deep immune profiling of MIS-C demonstrates marked but transient immune activation compared to adult and pediatric COVID-19. Sci. Immunol. 2021;6:eabf7570.
    1. Carter MJ, et al. Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection. Nat. Med. 2020;26:1701–1707.
    1. Pierce CA, et al. Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients. Sci. Transl. Med. 2020;12:eabd5487.
    1. Caldarale F, et al. Plasmacytoid dendritic cells depletion and elevation of IFN-γ dependent chemokines CXCL9 and CXCL10 in children with multisystem inflammatory syndrome. Front. Immunol. 2021;12:654587.
    1. Peart Akindele N, et al. Distinct cytokine and chemokine dysregulation in hospitalized children with acute COVID-19 and multisystem inflammatory syndrome with similar levels of nasopharyngeal SARS-CoV-2 shedding. J. Infect. Dis. 2021;224:606–615.
    1. Diorio, C. et al. Proteomic profiling of MIS-C patients reveals heterogeneity relating to interferon gamma dysregulation and vascular endothelial dysfunction. Preprint at medRxiv (2021).
    1. Zuo Y, et al. Neutrophil extracellular traps in COVID-19. JCI Insight. 2020;5:e138999.
    1. Middleton EA, et al. Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood. 2020;136:1169–1179.
    1. Yamashita K, Takaori-Kondo A, Mizugishi K. Exaggerated neutrophil extracellular trap formation in Kawasaki disease: a key phenomenon behind the outbreak in western countries? Ann. Rheum. Dis. 2020 doi: 10.1136/annrheumdis-2020-218593.
    1. Seery V, et al. Blood neutrophils from children with COVID-19 exhibit both inflammatory and anti-inflammatory markers. EBioMedicine. 2021;67:103357.
    1. Beckmann ND, et al. Downregulation of exhausted cytotoxic T cells in gene expression networks of multisystem inflammatory syndrome in children. Nat. Commun. 2021;12:4854.
    1. Vojdani A, Vojdani E, Kharrazian D. Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens: implications for autoimmune diseases. Front. Immunol. 2020;11:617089.
    1. An, H. & Park, J. Molecular mimicry map (3M) of SARS-CoV-2: prediction of potentially immunopathogenic SARS-CoV-2 epitopes via a novel immunoinformatic approach. Preprint at bioRxiv (2020).
    1. European Centre for Disease Prevention and Control. Rapid risk assessment: paediatric inflammatory multisystem syndrome and SARS-CoV-2 infection in children. (2020).
    1. Diorio C, et al. Evidence of thrombotic microangiopathy in children with SARS-CoV-2 across the spectrum of clinical presentations. Blood Adv. 2020;4:6051–6063.
    1. Whitworth HB, et al. Rate of thrombosis in children and adolescents hospitalized with COVID-19 or MIS-C. Blood. 2021;138:190–198.
    1. Endo Y, Takahashi M, Fujita T. Lectin complement system and pattern recognition. Immunobiology. 2006;211:283–293.
    1. Watanabe Y, Allen JD, Wrapp D, McLellan JS, Crispin M. Site-specific glycan analysis of the SARS-CoV-2 spike. Science. 2020;369:330–333.
    1. Polycarpou A, Grigoriadou S, Klavinskis L, Sacks S. Does the lectin complement pathway link Kawasaki disease and SARS-CoV-2? Front. Immunol. 2020;11:604512.
    1. Dove ML, et al. Multisystem inflammatory syndrome in children: survey of protocols for early hospital evaluation and management. J. Pediatr. 2021;229:33–40.
    1. Jonat B, et al. Multisystem inflammatory syndrome in children associated with coronavirus disease 2019 in a children’s hospital in New York City: patient characteristics and an institutional protocol for evaluation, management, and follow-up. Pediatr. Crit. Care Med. 2021;22:e178–e191.
    1. Ouldali N, et al. Association of intravenous immunoglobulins plus methylprednisolone vs immunoglobulins alone with course of fever in multisystem inflammatory syndrome in children. JAMA. 2021;325:855–864.
    1. McArdle AJ, et al. Treatment of multisystem inflammatory syndrome in children. N. Engl. J. Med. 2021;385:11–22.
    1. Guillaume M-P, Reumaux H, Dubos F. Usefulness and safety of anakinra in refractory Kawasaki disease complicated by coronary artery aneurysm. Cardiol. Young. 2018;28:739–742.
    1. Kone-Paut I, et al. The use of interleukin 1 receptor antagonist (anakinra) in Kawasaki disease: a retrospective cases series. Autoimmun. Rev. 2018;17:768–774.
    1. Jiang L, et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect. Dis. 2020;20:e276–e288.
    1. Feldstein LR, et al. Characteristics and outcomes of US children and adolescents with multisystem inflammatory syndrome in children (MIS-C) compared with severe acute COVID-19. JAMA. 2021;325:1074–1087.
    1. Hoste L, Van Paemel R, Haerynck F. Multisystem inflammatory syndrome in children related to COVID-19: a systematic review. Eur. J. Pediatr. 2021;180:2019–2034.
    1. Xu Q-Q, et al. Evaluation of left ventricular systolic strain in children with Kawasaki disease. Pediatr. Cardiol. 2014;35:1191–1197.
    1. Surve, S. V., Joseph, S., Gajbhiye, R. K., Mahale, S. D. & Modi, D. N. A systematic review on multisystem inflammatory syndrome in children (MIS-C) with COVID-19: development of a scoring system for clinical diagnosis. Preprint at medRxiv (2021).
    1. Sahoo, D. et al. An AI-guided invariant signature places MIS-C with Kawasaki disease in a continuum of host immune responses. Preprint at bioRxiv (2021).
    1. Newburger JW, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N. Engl. J. Med. 1991;324:1633–1639.
    1. Abrams JY, et al. Multisystem inflammatory syndrome in children associated with severe acute respiratory syndrome coronavirus 2: a systematic review. J. Pediatr. 2020;226:45–54.e1.
    1. Ouldali N, et al. Emergence of Kawasaki disease related to SARS-CoV-2 infection in an epicentre of the French COVID-19 epidemic: a time-series analysis. Lancet Child. Adolesc. Health. 2020;4:662–668.
    1. Choe YJ, et al. Surveillance of COVID-19-associated multisystem inflammatory syndrome in children, South Korea. Emerg. Infect. Dis. 2021;27:1196–1200.
    1. Li W, Tang Y, Shi Y, Chen Y, Liu E. Why multisystem inflammatory syndrome in children has been less commonly described in Asia? Transl. Pediatr. 2020;9:873–875.
    1. Son MBF, et al. Treatment of Kawasaki disease: analysis of 27 US pediatric hospitals from 2001 to 2006. Pediatrics. 2009;124:1–8.
    1. Coon ER, Wilkes J, Bratton SL, Srivastava R. Paediatric overdiagnosis modelled by coronary abnormality trends in Kawasaki disease. Arch. Dis. Child. 2018;103:937–941.
    1. Ghelani SJ, Kwatra NS, Spurney CF. Can coronary artery involvement in Kawasaki disease be predicted? Diagnostics. 2013;3:232–243.
    1. Gong GWK, McCrindle BW, Ching JC, Yeung RSM. Arthritis presenting during the acute phase of Kawasaki disease. J. Pediatr. 2006;148:800–805.
    1. Blondiaux E, et al. Cardiac MRI in children with multisystem inflammatory syndrome associated with COVID-19. Radiology. 2020;297:E283–E288.
    1. Gaitonde M, et al. COVID-19-related multisystem inflammatory syndrome in children affects left ventricular function and global strain compared with Kawasaki disease. J. Am. Soc. Echocardiogr. 2020;33:1285–1287.
    1. Jhaveri S, et al. Longitudinal echocardiographic assessment of coronary arteries and left ventricular function following multisystem inflammatory syndrome in children. J. Pediatr. 2020;228:290–293.
    1. Gamez-Gonzalez LB, et al. Kawasaki disease shock syndrome: unique and severe subtype of Kawasaki disease. Pediatr. Int. 2018;60:781–790.
    1. Tsuda E, et al. Changes in causes of sudden deaths by decade in patients with coronary arterial lesions due to Kawasaki disease. Cardiol. Young. 2005;15:481–488.
    1. Gatterre P, et al. Kawasaki disease: an unexpected etiology of shock and multiple organ dysfunction syndrome. Intensive Care Med. 2012;38:872–878.
    1. Kanegaye JT, et al. Recognition of a Kawasaki disease shock syndrome. Pediatrics. 2009;123:e783–e789.
    1. Li Y, et al. Kawasaki disease shock syndrome: clinical characteristics and possible use of IL-6, IL-10 and IFN-γ as biomarkers for early recognition. Pediatr. Rheumatol. 2019;17:1.
    1. Ma L, Zhang Y-Y, Yu H-G. Clinical manifestations of Kawasaki disease shock syndrome. Clin. Pediatr. 2018;57:428–435.
    1. Alsaied T, et al. Review of cardiac involvement in multisystem inflammatory syndrome in children. Circulation. 2021;143:78–88.
    1. Valverde I, et al. Acute cardiovascular manifestations in 286 children with multisystem inflammatory syndrome associated with COVID-19 infection in Europe. Circulation. 2021;143:21–32.
    1. Toubiana J, et al. Distinctive features of Kawasaki disease following SARS-CoV-2 infection: a controlled study in Paris, France. J. Clin. Immunol. 2021;41:526–535.
    1. Suzuki J, et al. Kawasaki disease shock syndrome in Japan and comparison with multisystem inflammatory syndrome in children in European countries. Front. Pediatr. 2021;9:625456.
    1. Kaneko K, Takahashi K, Fujiwara S, Maruyama T, Obinata K. Kawasaki disease followed by haemophagocytic syndrome. Eur. J. Pediatr. 1998;157:610–611.
    1. Cummings C, McCarthy P, van Hoff J, Porter G. Kawasaki disease associated with reactive hemophagocytic lymphohistiocytosis. Pediatr. Infect. Dis. J. 2008;27:1116–1118.
    1. Latino GA, Manlhiot C, Yeung RSM, Chahal N, McCrindle BW. Macrophage activation syndrome in the acute phase of Kawasaki disease. J. Pediatr. Hematol. Oncol. 2010;32:527–531.
    1. Natoli V, Rosina S, Ravelli A. Is macrophage activation syndrome in Kawasaki disease underrecognized? J. Rheumatol. 2021;48:162–164.
    1. Jinkawa A, et al. Cytokine profile of macrophage activation syndrome associated with Kawasaki disease. Cytokine. 2019;119:52–56.
    1. Aydın F, et al. Comparison of baseline laboratory findings of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis and multisystem inflammatory syndrome in children. Int. J. Rheum. Dis. 2021;24:542–547.
    1. Zulian F, et al. Acute surgical abdomen as presenting manifestation of Kawasaki disease. J. Pediatr. 2003;142:731–735.
    1. Miyake T, et al. Small bowel pseudo-obstruction in Kawasaki disease. Pediatr. Radiol. 1987;17:383–386.
    1. Halepas S, et al. Oral manifestations of COVID-2019-related multisystem inflammatory syndrome in children: a review of 47 pediatric patients. J. Am. Dent. Assoc. 2021;152:202–208.
    1. Saguil A, Fargo M, Grogan S. Diagnosis and management of Kawasaki disease. Am. Fam. Physician. 2015;91:365–371.
    1. Chen T-H, Kao W-T, Tseng Y-H. Gastrointestinal involvements in children with COVID-related multisystem inflammatory syndrome. Gastroenterology. 2020;160:1887–1888.
    1. LaRovere KL, et al. Neurologic involvement in children and adolescents hospitalized in the United States for COVID-19 or multisystem inflammatory syndrome. JAMA Neurol. 2021;78:536–547.
    1. Dengler LD, et al. Cerebrospinal fluid profile in patients with acute Kawasaki disease. Pediatr. Infect. Dis. J. 1998;17:478–481.
    1. Liu X, et al. Neurological involvement in Kawasaki disease: a retrospective study. Pediatr. Rheumatol. Online J. 2020;18:61.
    1. Kuo C-C, et al. Characteristics of children with Kawasaki disease requiring intensive care: 10 years’ experience at a tertiary pediatric hospital. J. Microbiol. Immunol. Infect. 2018;51:184–190.
    1. Radia T, et al. Multi-system inflammatory syndrome in children & adolescents (MIS-C): a systematic review of clinical features and presentation. Paediatr. Respir. Rev. 2020;38:51–57.
    1. Abrams JY, et al. Factors linked to severe outcomes in multisystem inflammatory syndrome in children (MIS-C) in the USA: a retrospective surveillance study. Lancet Child. Adolesc. Health. 2021;5:323–331.
    1. Ouldali N, et al. Factors associated with severe SARS-CoV-2 infection. Pediatrics. 2021;147:e2020023432.
    1. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘cytokine storm’ in COVID-19. J. Infect. 2020;80:607–613.
    1. Dolinger MT, et al. Pediatric Crohn disease and multisystem inflammatory syndrome in children (MIS-C) and COVID-19 treated with infliximab. J. Pediatr. Gastroenterol. Nutr. 2020;71:153–155.
    1. Esteve-Sole A, et al. Similarities and differences between the immunopathogenesis of COVID-19-related pediatric multisystem inflammatory syndrome and Kawasaki disease. J. Clin. Invest. 2021;131:e144554.
    1. Al-Ghafry M, et al. Multisystem inflammatory syndrome in children (MIS-C) and the prothrombotic state: coagulation profiles and rotational thromboelastometry in a MIS-C cohort. J. Thromb. Haemost. 2021;19:1764–1770.
    1. Martinez OM, Bridges ND, Goldmuntz E, Pascual V. The immune roadmap for understanding multi-system inflammatory syndrome in children: opportunities and challenges. Nat. Med. 2020;26:1819–1824.
    1. Shobhavat L, et al. Multisystem inflammatory syndrome in children: clinical features and management-intensive care experience from a pediatric public hospital in western India. Indian. J. Crit. Care Med. Peer Rev. 2020;24:1089–1094.
    1. Niño-Taravilla C, Otaola-Arca H, Lara-Aguilera N, Zuleta-Morales Y, Ortiz-Fritz P. Multisystem inflammatory syndrome in children, Chile, May-August 2020. Emerg. Infect. Dis. 2021;27:1457–1461.
    1. Tolunay O, et al. Multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19: a case series experience in a tertiary care hospital of southern Turkey. J. Trop. Pediatr. 2021;67:fmab050.
    1. Young TK, et al. Mucocutaneous manifestations of multisystem inflammatory syndrome in children during the COVID-19 pandemic. JAMA Dermatol. 2021;157:207–212.
    1. Newburger Jane W, et al. Diagnosis, treatment, and long-term management of Kawasaki disease. Circulation. 2004;110:2747–2771.
    1. Ozdemir H, et al. Clinical and epidemiological characteristics of children with Kawasaki disease in Turkey. J. Trop. Pediatr. 2010;56:260–262.
    1. Fukushige J, Takahashi N, Ueda Y, Ueda K. Incidence and clinical features of incomplete Kawasaki disease. Acta Paediatr. Oslo. Nor. 1994;83:1057–1060.
    1. Sung RYT, et al. Lack of association of cervical lymphadenopathy and coronary artery complications in Kawasaki disease. Pediatr. Infect. Dis. J. 2006;25:521–525.
    1. Smith LB, Newburger JW, Burns JC. Kawasaki syndrome and the eye. Pediatr. Infect. Dis. J. 1989;8:116–118.
    1. Baker AL, et al. Associated symptoms in the ten days before diagnosis of Kawasaki disease. J. Pediatr. 2009;154:592–595.e2.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren